The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients. The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig ...

The FDA approved the use of pembrolizumab (Keytruda; Merck) and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for use in patients 12 years and older with solid tumor indications approved for the ...

The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged.

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...